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Purpose
Various tumor antigens can be loaded onto dendritic cells (DCs) to induce a potent cytotoxic T
lymphocyte (CTL) response in DC-based immunotherapy against breast cancer. However, in
the clinical setting, obtaining a sufficient number of autologous tumor cells as a source of tumor
antigens is a laborious process. We therefore investigated the feasibility of immunotherapy
using breast-cancer-specific CTLs generated in vitro by use of alpha-type 1 polarized DCs (α
DC1s) loaded with ultraviolet B-irradiated cells of the breast cancer cell line MCF-7.
Materials and Methods
α DC1s were induced by loading allogeneic tumor antigen generated from the MCF-7 UVB-
irradiated breast cancer cell line. Antigen-pulsed α DC1s were evaluated by morphological
and functional assays, and the breast-cancer-specific CTL response was analyzed by cyto-
toxic assay.
Results
The α DC1s significantly increased the expression of several molecules related to DC
maturation without differences according to whether the α DC1s were loaded with tumor
antigens. The α DC1s showed a high production of interleukin-12 both during maturation and
after subsequent stimulation with CD40L, which was not significantly affected by loading
with tumor antigens. Breast-cancer-specific CTLs against autologous breast cancer cells
were successfully induced by α DC1s loaded with apoptotic MCF-7 cells.
Conclusion
Autologous DCs loaded with an allogeneic breast cancer cell line can generate potent
breast-cancer-specific CTL responses. This may be a practical method for cellular immuno-
therapy in patients with breast cancer.
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Introduction
Breast cancer is one of the most common malignancies in women
and is the second leading cause of cancer death [1]. In the modern
era of breast cancer treatment, rapid progress has led to a broad
spectrum of therapeutic strategies for improving clinical outcomes.
In addition to improvements in therapeutic modalities including
chemotherapy, radiation, hormone manipulation and surgery, immu-
notherapy has emerged as an effective adjunct for the treatment of
breast cancer [2,3]. The possible use of immunotherapy in breast
cancer treatment was suggested by several findings. One such finding
was the detection of a protective effect of human leukocyte antigen
(HLA) class II alleles in breast cancer [4,5]. Another finding was
that T cells recognizing mucin (MUC)-1 and HER2/neu-derived
antigens could be isolated from the peripheral blood of breast cancer
patients [5,6]. Furthermore, graft-versus-tumor effects were shown
to be induced by donor lymphocyte infusion in patients who relapsed
after allogeneic stem cell transplantation [7]. 
Dendritic cells (DCs) are the major antigen-presenting cells of the
immune system. Because of their ability to stimulate T cells, DCs
act as a link in antitumor immune responses between innate immunity
and adaptive immunity [8]. Once activated by inflammatory stimuli
or infectious agents, immature DCs undergo maturation, which
results in the expression of high levels of major histocompatibility
complex (MHC) and co-stimulatory molecules which present antigens
to activate T cells [9]. DC-based vaccines are the most attractive tool
for cancer immunotherapy and have been used in more than 20
malignancies; most commonly melanoma, prostate cancer, colorectal
carcinoma and multiple myeloma. In an attempt to increase the
potency of DCs, alpha-type 1 polarized DCs (α DC1s) were developed
through the use of cytokine combinations. The α DC1s are induced
to mature by addition of an α DC1-polarizing cytokine cocktail
containing interleukin (IL)-1β , tumor necrosis factor (TNF)-α ,
interferon (IFN)-α , IFN-γand polyinosinic : polycytidylic acid
[poly(I : C)]). Compared with standard DCs, α DC1s generate strong,
functional cytotoxic T lymphocytes (CTLs) in several diseases[10,11]. 
The ideal DC-based vaccination in breast cancer would induce
tumor-specific immunity to breast cancer without causing clinically
significant autoimmunity. One approach to enhancing the specificity
of vaccines is to target them against specific protein antigens that are
over-expressed on breast cancer cells. These tumor antigens, such as
MUC-1, HER2/neu and telomerase, are also expressed on tumor
cells of other epithelial-derived cancers and are loaded onto DCs as
a source of tumor antigen which will not target multiple tumor
variants [12-14]. The use of whole tumor cells instead of a single
protein antigen for tumor antigen in DCs, may help to enhance breast
cancer-specific cytolytic effects with unfractionated tumor-derived
antigens. However, it is not only impractical to obtain sufficient
amounts of purified autologous tumor cells for tumor antigens from
Events
10
4
10
0
A2
10
1
10
2
10
3
128
0
Fresh blood from
breast cancer patients
with HLA-A0201
+
Lymphoprep
Percoll
PBMCs
Lymphocyte fraction CD3
+
MCF-7 breast cancer cells
UVB irradiation followed
by culturing in RPMI
without FBS
Apoptotic tumor cells
2 hrs after the addition of cytokines
2 : 1 ratio (DCs : tumor cells)
DC1 D8
D0
D2, D4
D6
Monocytes
Adhesion for 45 min
Monocyte fraction
(5x10 /mL/well)
5
GM-CSF+IL-4
Immature DCs

 
DC1-polarizing cocktail
(TNF- , IL-1 , IFN- , IFN- , Poly-I : C)
Media: IMDM with 10% FBS
Cytokines: GM-CSF (50 ng/mL), IL-4 (20 ng/m ), TNF- (50 ng/ ), IL-1 (25 ng/m ),
IFN- (3,000 U/m ), IFN- (1,000 U/m ), Poly-I : C (20 g/m )
Lm L L
LL L

 
Fig. 1. Schema of the generation of dendritic cells (DCs) in patients with breast cancer in this study. PBMCs, peripheral blood mononuclear cells; D,
day; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; poly-I : C, polyinosinic :
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breast cancer patients, but it is also unsuitable for those with a lower
tumor-burden status. Therefore, to overcome this limitation, allogeneic
tumor cells or established cancer cell lines from various tumors have
been used as an alternative source of tumor-relevant antigens [15-17].
In the present study, we investigated the possibility of immu-
notherapy using autologous α DC1s loaded with ultraviolet B (UVB)-
irradiated cells from the allogeneic breast cancer cell line MCF-7.
We studied whether these cells could generate breast-cancer-specific
CTLs against autologous cancer cells in patients with breast cancer. 
Materials and Methods
1 Generation of α α DC1s
The schema for the generation of DCs is shown in Fig. 1. Peri-
pheral blood was collected from HLA-A0201-positive (HLA-A0201
+)
breast cancer patients after obtaining informed consent according to
the protocol approved by the Chonnam National University Hwasun
Hospital Institutional Review Board. Monocytes were isolated from
peripheral blood by a two-step procedure as previously reported
[18]. Briefly, mononuclear cells were isolated from the peripheral
blood by density gradient centrifugation with Ficoll-Hypaque
(Lymphoprep, Nycomed, Norway). The monocyte and lymphocyte
fractions were isolated on density gradients with Percoll (Sigma-
Aldrich, St. Louis, MO). The monocyte fraction was resuspended in
AIM-V medium (Gibco-BRL, Grand Island, NY) at a density of 5
×10
5 cells/500 μ L and was allowed to adhere to 24-well plates for
45 minutes at 37℃in 5% CO2. 
After removal of nonadherent cells by gentle washing, immature
DCs were generated by culturing the adhered monocytes in IMDM
(Gibco-BRL) supplemented with 10% heat-inactivated fetal bovine
serum (Hyclone, Logan, UT) and 1% penicillin-streptomycin (Gibco-
BRL) for 6 days in 24-well plates at a density of 5×10
5 cells per
well, in the presence of 50 ng/mL granulocyte-macrophage colony-
stimulating factor (LG Biochemical, Daejeon, Korea) and 20 ng/mL
IL-4 (R&D Systems, Minneapolis, MN). On day 6, the immature
DCs were maturated with an α DC1-polarizing cocktail composed of
IL-1β(25 ng/mL), TNF-α(50 ng/mL), IFN-α(3,000 units/mL,
Intron-A-IFN-α -2b, Schering-Plough, Kenilworth, NJ), IFN-γ(1,000
units/mL, Strathmann Biotech, Hamburg, Germany) and poly(I : C)
(20 μ g/mL, Sigma-Aldrich). The mature α DC1s were then loaded
with the UVB-irradiated tumor cells (HLA-A0201
+) at a ratio of 2 : 1
at 2 hours after the addition of the maturating cytokines. The α DC1s
loaded with apoptotic tumor cells were harvested on day 8. 
2 Preparation of the UVB-irradiated tumor cells as an
antigen source
To load tumor cells onto DCs, MCF-7 breast cancer cells (HLA-
A0201
+, adenocarcinoma, estrogen receptor positive) were irradiated
with UVB (120 mJ/cm
2) followed by overnight culture in RPMI-
1640 (Gibco-BRL) without fetal bovine serum to induce apoptosis
and were then thoroughly washed. The irradiated tumor cells were
then loaded onto DCs 2 hours after the addition of maturating
cytokines. The irradiated apoptotic cells were immediately confirmed
by using annexin-V and propidium iodide (data not shown).
3 Preparation of breast cancer cells
Tumor tissues obtained from breast cancer patients by surgical
resection were minced and lysed for 2-4 hours at 37℃ in AIM-V
medium containing 0.4% collagenase type III. The mononuclear
cells were separated by density gradient centrifugation with Ficoll-
Hypaque (Lymphoprep) and cryopreserved until use as target cells
in the cytotoxic assay. 
4 Phenotypic expression of α α DC1s and tumor-antigen
uptake 
Flow cytometry was performed using a FACSAria cell sorter
(Beckon Dickinson, San Jose, CA) after labeling of cells with CD83-
fluorescein isothiocyanate (FITC), CD86-FITC, and CCR7-FITC
(PharMingen, San Diego, CA) and the relevant isotype controls
(mouse IgG1 and IgG2a, PharMingen). Cell debris was eliminated
from the analysis by forward- and side-scatter gating, and the data
were analyzed with FACSDiva
TM (Becton Dickinson, Heidelberg,
Germany) and Win MDI ver. 2.9 (Bio-Soft Net). 
To measure tumor-antigen uptake by α DC1s, MCF-7 cells were
labeled with PKH67-GL-FITC (Sigma-Aldrich) before UVB-irra-
diation. After loading of tumor antigen onto DCs at a ratio of 1 : 2
on day 6, the α DC1s loaded with the apoptotic MCF-7 cells were
stained with CD11c-phycoerythrin (PE) after harvesting on day 8
and were then analyzed by flow cytometry for tumor cell uptake
(CD11c
+/PKH67
+). To morphologically confirm the tumor uptake of
α DC1s, MCF-7 cells were labeled with PKH67-GL-Green and DCs
were labeled with PKH26-GL-Red. The morphology of the cells’ nuclei
was observed by using a confocal microscope (Olympus, Center
Valley, PA) at an excitation wave length of 350 nm for 4’, 6-diami-
dino-2-phenylindole (DAPI) staining.
5 Cytokine analyses by enzyme-linked immunosorbent
assay (ELISA)
The levels of IL-12p40, IL-12p70, IL-10 and IL-6 in the primary
culture supernatants of the α DC1s were measured using Quantikine
Immunoassay Kits (R&D Systems). Additionally, α DC1s harvested
on day 8 were plated in 96-well plates at a density of 2×10
4cells/well
and were stimulated with CD40L-transfected J558 cells (as an
analogue of CD40L-expressing Th cells; a kind gift of Dr. P. Lane,Min-Ho Park, et al_Allogeneic Tumor Antigen for α DC1s
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University of Birmingham, UK) at a density of 5×10
4 cells/well.
After 24 hours, the supernatant was harvested, and the production of
IL-12p70 was measured using ELISA kits (R&D Systems). 
6 Allogeneic T cell stimulatory capacities
To examine the capacity of the DCs to stimulate the alloreactive
T cells, allogeneic CD3
+ T cells were obtained from peripheral
blood mononuclear cells (PBMCs) from healthy donors by positive
selection, using the magnetic activated cell sorter (MACS) system
(Miltenyi Biotec, Auburn, CA). T cells (1×10
6 cells) were labeled
with 10 μ M carboxyfluorescein diacetate succinimidyl ester (CFSE;
Molecular Probes
TM, Invitrogen, Paisley, UK) for 10 minutes at 37℃.
After 2 washes, the CFSE-labeled T cells (2×10
4) were co-cultured
with graded doses of irradiated (30 Gy) DCs. On day 5, the cultured
cells were harvested and acquired on a FACSAria cell sorter
(Becton Dickinson), and the data were analyzed with WinMDI ver.
2.9 software (Bio-Soft Net) to detect the dilution of CFSE dye. The
results are expressed as the percentage of proliferated cells. 
7 In vitropriming of CD4
+CD45RA
+naïve T cells with DCs
Naïve CD4
+ T cells were obtained from PBMCs of healthy volun-
teers by a negative selection process using a naïve CD4
+ T isolation
kit (MACS, Miltenyi Biotec). Purity of the isolated CD45RA
+cells
was＞95%, as determined by FACS assay with CD4-FITC and
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CD45RA-PE staining. CD4
+CD45RA
+ naïve T cells (2×10
4) were
stimulated with 2×10
4 matured DCs that had been pre-incubated
with 1 ng/mL of Staphylococcus aureus enterotoxin B in 96-well
flat-bottomed plates. On day 5, 10 U/mL rIL-2 (R&D Systems) was
added to each well. After 5 days, the cells were stimulated for 1 day
with Dynabeads CD3/CD28 T Cell Expander (Invitrogen Dynal
AS, Oslo, Norway). Supernatants from the re-stimulated cultures
were assayed for Th1 cytokine, IFN-γ , and the Th2 cytokine, IL-4,
using the BD OptEIA ELISA Set (BD Bioscience, San Diego, CA).
The production of Th1- and Th2-type cytokines at the single-cell
level was measured by FACS analysis, using an intracellular
cytokine staining protocol, as described previously [19]. Briefly,
harvested T cells were stimulated with phorbol myristate acetate and
ionomycin for 5 hours, and Brefeldin A (eBiosciences, San Diego,
CA) was added during the last 2 hours of incubation. Cells were
collected, fixed, permeabilized with a commercial IntraPrep Per-
meabilization Reagent (Beckman Coulter, Marseille, France) and
were stained with FITC-labeled IFN-γand PE-labeled IL-4 mAbs.
The samples were acquired on a FACSAria cell sorter (Becton Dic-
kinson) and were analyzed using WinMDI ver. 2.9 (Bio-Soft Net).
8 Induction of breast-cancer-specific CTLs
Autologous CD3
+ T cells (purity＞90%) were positively isolated
using MACS (Miltenyi Biotec) from the lymphocyte fraction after
Percoll isolation. T cells (1×10
6 cells) were sensitized by auto-
logous α DC1s (1×10
5 cells) primed with apoptotic MCF7 cells. On
day 3, rhuIL-2 (25 ng/mL, R&D Systems) and IL-7 (10 ng/mL,
R&D Systems) were added. On day 10, the CTL lines were re-
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stimulated with the same DCs. On day 20, the number of antigen-
specific T cells was analyzed by IFN-γenzyme-linked immunospot
(ELISPOT) assay. Autologous MCF-7 cells (HLA-A0201
+ breast
cancer cells), T-47D (HLA-A0201
- breast cancer cells), PC-3
(prostate cancer cells) and K562 cells (chronic myeloid leukemia
cells with natural killer [NK] cell activity) were used as target cells.
To distinguish MHC-restricted cytotoxicity in CTL lines, IFN-γ -
secreting cells were measured in the presence or absence of the
mAbs W6/32 (MHC I antigen, 10 μ g/mL). Additionally, autologous
breast cancer cells obtained from patients were used as target cells
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with or without anti-MHC I antibody. The ELISOPT data were ex-
pressed as the mean number of spots (±standard deviation) per 0.5-2×
10
5T cells.
Results
1 Characteristics of mature and polarized DCs in patients
with breast cancer
After induction of the immature DCs, α DC1s were generated by
addition of the α DC1 cytokine cocktail. The α DC1s showed typical
morphology with large and branching structures that were aggre-
gated among the cells. Phenotypic analysis showed that expressions
of maturation marker (CD83), co-stimulatory molecule (CD86) and
the predictive marker of migratory ability (CCR7) were significantly
higher in α DC1s than in immature DCs. However, there were no
differences in phenotypic expression between the α DC1s and the
α DC1s loaded with apoptotic MCF-7 cells (Fig. 2). 
To measure tumor antigen uptake by DCs, DCs loaded with
apoptotic tumor cells were stained with CD11c. As shown in Fig. 3A,
α DC1s very efficiently incorporated the tumor antigen (median,
22.3±8.5%; n=4) as measured by flow cytometry (CD11c
+/PKH-67
+).
By use of a confocal microscope, apoptotic MCF-7 cells (PKH-67)
were morphologically identified in the α DC1s (PKH-26) (Fig. 3B). 
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2 High level of IL-12p70 production by α α DC1s in breast 
cancer
One of best ways of determining DC function is to examine cyto-
kine secretion. IL-12p70 is an important cytokine for stimulating
naïve T cells for Th1 polarization to benefit cancer treatment, but
IL-10 is the main inhibitory cytokine for cancer treatment. As shown
in Fig. 4, the α DC1s showed high IL-12p70 production during
maturation. Furthermore, the α DC1s showed further production of
IL-12p70 after subsequent stimulation with CD40L-transfected J558
cells (Fig. 4). This cytokine capacity of α DC1s was not significantly
suppressed by loading the cells with tumor antigen. By contrast,
production of the inhibitory cytokine IL-10 by α DC1s was not
significant. IL-6 production was significantly higher by the α DC1s
than by the immature DCs, which is consistent with the finding of a
previous report [20], suggesting Th17 polarization of α DC1s. 
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Fig. 6. Comparison of allogeneic T cell stimulatory capacities of dendritic cells (DCs). In a carboxyfluorescein diacetate succinimidyl ester
(CFSE)-based proliferation assay, CFSE-labeled allogeneic CD3
+ T cells (20,000 cells/well) were stimulated for 5 days with graded doses of
irradiated DCs. Flow cytometry was used to measure the percent of CFSE-proliferated cells. The stimulatory capacity of the alpha-type 1 pola-
rized DCs (α DC1s) was significantly higher in a dose-dependent manner than that of the immature DCs (iDCs), and there was no effect on T cell
proliferation by loading of apoptotic tumor cells onto α DC1s. Data are representative histograms of fluorescence-activated cell sorting analysis
from one of three independent experiments.Cancer Res Treat. 2011;43(1):56-66
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3 α α DC1s in patients with breast cancer promoted Th1
polarization of naïve T cells 
To confirm whether the α DC1s could induce the differentiation of
naïve T cells toward Th1, the naïve T cells were stimulated by the
DCs. The α DC1s induced naïve T cells to not only increase the level
of IFN- γsecretion but also decrease the level of IL-4 secretion (Fig.
5A). This finding suggests that α DC1s strongly promote Th1 pola-
rization of naïve T cells in patients with breast cancer. This Th1
response was confirmed by flow cytometry to analyze the produc-
tion of Th1-type and Th2-type cytokines at the single-cell level. The
α DC1s could induce Th1 polarization (IFN-γproducing cells:
46.9%) compared with immature DCs (30.3%) (Fig. 5B).
4 α α DC1s in patients with breast cancer showed strong
allogeneic T cell stimulatory capacities 
To evaluate the ability of DCs to stimulate T cell proliferation,
allogeneic CD3
+ T cells obtained from healthy donors were stimu-
lated with DCs and an allogeneic mixed lymphocyte reaction assay
was performed using the CFSE-based proliferation assay. As shown
in Fig. 6, the percentage of proliferated T cells was significantly
higher after stimulation of α DC1s than after stimulation of immature
DCs and was dependent on the DC to T cell ratio. Loading of apoptotic
tumor cells onto α DC1s did not significantly affect T cell proliferation. 
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Fig. 7. Ezyme-linked immunospot (ELISPOT) assay to measure the
interferon (IFN)-γrelease of breast-cancer-specific cytotoxic T lym-
phocytes (CTLs). Autologous CD3
+ T cells were stimulated with
dendritic cells (DCs) loaded with apoptotic MCF-7 cells two times
every 10 days. On day 20, the CTLs were co-cultured with autologous
target cells (MCF-7, HLA-A0201
+) and irrelevant target cells (T-47D,
HLA-A0201
- breast cancer cells; PC3, prostate cancer cells; K562,
natural killer cell-sensitive chronic myeloid leukemia cells). (A)
Number of IFN-γ -secreting cells from CTLs stimulated with the
MCF-7-loaded-alpha-type 1 polarized DCs (α DC1s) (A) and the
MCF-7-unloaded-α DC1s (B). Anti-major histocompatibility
complex (MHC) class I antibodies were used to confirm the MHC
class I-restricted recognition of breast-cancer-specific CTLs. Breast
cancer cells were isolated from tumor tissue of patients and the CTLs
were co-cultured with the breast cancer cells as target cells (C). The
ELISPOT data are the mean (±standard deviation) number of IFN-γ -
producing cells of triplicate cultures in three independent experiments.Min-Ho Park, et al_Allogeneic Tumor Antigen for α DC1s
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5 Strong breast-cancer-specific CTLs were induced by 
potent DCs loaded with apoptotic allogeneic breast
cancer cells
We next determined the tumor-specific generation of CTLs by
DCs. The secretion of IFN-γby the CTLs was measured in three
independent experiments using the ELISPOT assay. Primed CD3+
T cells generated by the α DC1s loaded with apoptotic MCF-7 breast
cancer cells, showed a larger number of IFN-γ -producing cells
against MCF-7 breast cancer cells (Fig. 7A) and against autologous
breast cancer cells obtained from breast tumor tissue (Fig. 7C), but
not against irrelevant target cells such as T-47D (HLA-A0201
-
breast cancer cells) and PC-3 (prostate cancer cells). The specificity
of the CTL response was confirmed by inhibition of IFN-γ -release
with MHC class I-blocking mAb, indicating HLA class I-restricted
action. When we used α DC1s without loading of apoptotic breast
cancer cells as a control, the CTLs generated showed a fewer
number of IFN-γ -producing cells against MCF-7 breast cancer cells
(Fig. 7B). To evaluate the specificity of the cytotoxic response by
CTLs, K562 cells, which are NK cell-sensitive chronic myeloid
leukemia cells, were used as the target cells. Fewer IFN-γ -secreting
cells were found against K562, which suggests a CTL-mediated,
rather than an NK cell-mediated breast cancer response. 
Discussion
The development of breast cancer immunotherapies using mole-
cular typing or genomic identification of breast cancer antigen has
confirmed that specific biological types of breast cancer exist with
different levels and patterns of antigen expression [21,22]. The
identification of multiple antigenic targets in breast cancer should
enable a potent antigen-specific immune response. In this report we
have suggested an alternative approach to immunotherapy in which
allogeneic cancer cells are used as a tumor-specific antigen for
loading onto DCs. We successfully generated α DC1s from breast
cancer patients, and the cells showed a high expression level for
molecules related to DC maturation, significant production of IL-
12p70, and potent generation of breast-cancer-specific CTLs. Add-
itionally, the α DC1s demonstrated strong IL-12p70 production after
CD40L stimulation and had a potent capacity to induce Th1 polari-
zation on the basis of their high production of IFN-γ . The CTLs
generated by the α DC1s demonstrated breast-cancer-specific killing
effects in an MHC class I-restricted manner.  
In clinical practice, allogeneic breast cancer cells prepared from
MCF-7 cells might be an effective source of universal tumor antigen
that could be used for loading onto α DC1s for the generation of
breast-cancer-specific CTLs. This approach is similar to recent studies
in other diseases showing that fusion cells generated by autologous
DCs and allogeneic tumor cell lines could generate antigen-specific
CTL responses [23,24]. The use of allogeneic cancer cells can avoid
the necessary process of original tumor cell collection and simplify
the culture of tumor cells [23,25]. Vaccination with autologous DCs
primed with allogeneic tumor cell lines has potential applicability to
the field of antitumor immunotherapy. These universal cell lines
would provide several advantages for clinical applications, such as
no limiting factor affecting tumor cell preparation and well-cha-
racterized features as a source of tumor-associated antigens. 
We demonstrated that autologous α DC1s loaded with apoptotic
MCF-7 cells could prime T cells to generate the tumor-specific
CTLs, which can kill breast cancer cells. More importantly, the
pulsed α DC1s from the HLA-A0201
+ patients could induce CTL
activity against autologous breast cancer cells, and the pulsed α
DC1s from HLA0201
- patients generated a breast-cancer-specific
CTL response with less potency than the response generated from
HLA0201
+ cells. The autologous α DC1s pulsed with apoptotic
MCF-7 cells from HLA-A0201
+ patients could stimulate allore-
active T cells due to the presence of allogeneic HLA class I molecules
from an allogeneic breast cancer cell line. Moreover, alloreactive T
cells could secrete cytokines, which may contribute to enhancement
or maintenance of the tumor-specific CTL response. The inhibition
of MHC class molecules by use of anti-MHC class antibody pre-
vented the development of CTL responses specific for autologous
breast cancer cells from HLA-A0201
+ patients. Thus, the use of an
allogeneic tumor cell line as a source of tumor antigens could gene-
rate MHC class-restricted T cell responses against autologous breast
cancer cells. A major drawback of this approach is the need to
perform HLA typing of patients and allogeneic tumor cell lines. 
Conclusion
In this study, autologous α DC1s loaded with allogeneic breast
cancer cells could generate strong breast-cancer-specific CTLs
against autologous breast cancer cells. This may offer a highly
feasible and effective method for cell-based immunotherapy in patients
with breast cancer. 
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